Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform …
FPB Kroon, A Najm, A Alunno, JW Schoones… - Annals of the …, 2022 - ard.bmj.com
Objectives Perform a systematic literature review (SLR) on risk and prognosis of SARS-CoV-
2 infection and vaccination against SARS-CoV-2 in patients with rheumatic and …
2 infection and vaccination against SARS-CoV-2 in patients with rheumatic and …
Insights into SARS-CoV-2 persistence and its relevance
BA Desimmie, YY Raru, HM Awadh, P He, S Teka… - Viruses, 2021 - mdpi.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
coronavirus disease 2019 (COVID-19), continues to wreak havoc, threatening the public …
coronavirus disease 2019 (COVID-19), continues to wreak havoc, threatening the public …
[HTML][HTML] Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global …
JA Sparks, ZS Wallace, AM Seet… - Annals of the …, 2021 - ard.bmj.com
Objective To investigate baseline use of biologic or targeted synthetic (b/ts) disease-
modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis …
modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis …
EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November …
RBM Landewé, FPB Kroon, A Alunno, A Najm… - Annals of the …, 2022 - ard.bmj.com
The first EULAR provisional recommendations on the management of rheumatic and
musculoskeletal diseases (RMDs) in the context of severe acute respiratory syndrome …
musculoskeletal diseases (RMDs) in the context of severe acute respiratory syndrome …
COVID-19 vaccine effectiveness against omicron (B. 1.1. 529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective …
Background There is a scarcity of research regarding the effectiveness of the mRNA-1273
(Moderna) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in patients taking …
(Moderna) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in patients taking …
[HTML][HTML] Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной …
ЕЛ Насонов, АМ Лила, ВИ Мазуров… - Научно …, 2021 - cyberleninka.ru
В середине 2021 года инфекция SARS-CoV-2 (Severe Acute Respiratory coronavirus 2),
вызвавшая пандемию коронавирусной болезни 2019 (coronavirus disease, COVID-19) …
вызвавшая пандемию коронавирусной болезни 2019 (coronavirus disease, COVID-19) …
DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: a prospective …
Objective To describe disease-modifying antirheumatic drug (DMARD) disruption, rheumatic
disease flare/activity, and prolonged COVID-19 symptom duration among COVID-19 …
disease flare/activity, and prolonged COVID-19 symptom duration among COVID-19 …
Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis
LE Bartels, C Ammitzbøll, JB Andersen, SR Vils… - Rheumatology …, 2021 - Springer
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were
launched in December 2020. Vaccination of patients with rheumatic diseases is …
launched in December 2020. Vaccination of patients with rheumatic diseases is …
Soluble urokinase plasminogen activator receptor (suPAR) independently predicts severity and length of hospitalisation in patients with COVID-19
H Enocsson, C Idoff, A Gustafsson, M Govender… - Frontiers in …, 2021 - frontiersin.org
Background: Efficient healthcare based on prognostic variables in hospitalised patients with
COVID-19 could reduce the risk of complications and death. Recently, soluble urokinase …
COVID-19 could reduce the risk of complications and death. Recently, soluble urokinase …
TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD
AC Regierer, R Hasseli, M Schäfer, BF Hoyer… - RMD open, 2021 - rmdopen.bmj.com
Introduction Several risk factors for severe COVID-19 specific for patients with inflammatory
rheumatic and musculoskeletal diseases (RMDs) have been identified so far. Evidence …
rheumatic and musculoskeletal diseases (RMDs) have been identified so far. Evidence …